141 related articles for article (PubMed ID: 30932446)
21. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
22. Successful Treatment of CINCA/NOMID Syndrome with Interleukin-1 Blockade.
Macejová Z; Vargová V; Matejka M; Szekanecz Z
Isr Med Assoc J; 2015 Jun; 17(6):389-91. PubMed ID: 26234003
[No Abstract] [Full Text] [Related]
23. Anakinra for cryopyrin-associated periodic syndrome.
Koné-Paut I; Galeotti C
Expert Rev Clin Immunol; 2014 Jan; 10(1):7-18. PubMed ID: 24308832
[TBL] [Abstract][Full Text] [Related]
24. [Cryopyrin-associated periodic syndromes].
Quartier P; Rodrigues F; Georgin-Lavialle S
Rev Med Interne; 2018 Apr; 39(4):287-296. PubMed ID: 29111302
[TBL] [Abstract][Full Text] [Related]
25. Neonatal treatment of CINCA syndrome.
Paccaud Y; Berthet G; Von Scheven-Gête A; Vaudaux B; Mivelaz Y; Hofer M; Roth-Kleiner M
Pediatr Rheumatol Online J; 2014; 12():52. PubMed ID: 25584041
[TBL] [Abstract][Full Text] [Related]
26. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
27. Muckle-Wells syndrome/neonatal-onset multisystem inflammatory disease overlap associated with myelodysplasia and cerebrovascular accident.
Madan V; Kingston H; Jamieson LA; Goyal N; Ead R
Clin Exp Dermatol; 2010 Oct; 35(7):752-5. PubMed ID: 20456407
[TBL] [Abstract][Full Text] [Related]
28. [IL-1 antagonists].
Kötter I; Horneff G
Z Rheumatol; 2010 Sep; 69(7):581-93. PubMed ID: 20703489
[TBL] [Abstract][Full Text] [Related]
29. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.
Sibley CH; Chioato A; Felix S; Colin L; Chakraborty A; Plass N; Rodriguez-Smith J; Brewer C; King K; Zalewski C; Kim HJ; Bishop R; Abrams K; Stone D; Chapelle D; Kost B; Snyder C; Butman JA; Wesley R; Goldbach-Mansky R
Ann Rheum Dis; 2015 Sep; 74(9):1714-9. PubMed ID: 24906637
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 4. Interleukin-1 inhibitor].
Yamasaki S; Kawakami A
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2985-90. PubMed ID: 22175142
[No Abstract] [Full Text] [Related]
31. CINCA syndrome in an infant presenting with hydrocephalus.
Turel O; Goknar N; Uzuner S; Kasapcopur O; Cuisset L
Int J Rheum Dis; 2014 Mar; 17(3):346-8. PubMed ID: 24618115
[No Abstract] [Full Text] [Related]
32. Canakinumab for the treatment of cryopyrin-associated periodic syndromes.
Walsh GM
Drugs Today (Barc); 2009 Oct; 45(10):731-5. PubMed ID: 20069137
[TBL] [Abstract][Full Text] [Related]
33. Severe cryopyrin-associated periodic syndrome first characterized by early childhood-onset sensorineural hearing loss - Case report and literature review.
Hui A; Johnson LB; Greemberg R; Penney L; Ramsey SE
Int J Pediatr Otorhinolaryngol; 2019 May; 120():68-72. PubMed ID: 30772614
[TBL] [Abstract][Full Text] [Related]
34. CRYOPYRIN-ASSOCIATED PERIODIC SYNDROME-ASSOCIATED UVEITIS AND PAPILLITIS.
Ma L; Lee S; Montieth A; Stephenson A; Foster CS; Anesi SD
Retin Cases Brief Rep; 2021 Mar; 15(2):149-154. PubMed ID: 30134363
[TBL] [Abstract][Full Text] [Related]
35. Muckle-Wells syndrome: manifestations and diagnosis in four generations of a Portuguese family.
Azevedo SRL; Peixoto DFM
World J Pediatr; 2020 Oct; 16(5):541-542. PubMed ID: 32246440
[No Abstract] [Full Text] [Related]
36. Resolution of femoral metaphyseal dysplasia in CINCA syndrome after long-term treatment with interleukin-1 blockade.
Rigante D; Manna R; Verrecchia E; Marrocco R; Leone A
Clin Rheumatol; 2018 Jul; 37(7):2007-2009. PubMed ID: 29766377
[TBL] [Abstract][Full Text] [Related]
37. [Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra].
Klein AK; Horneff G
Klin Padiatr; 2010 Jul; 222(4):266-8. PubMed ID: 20135584
[TBL] [Abstract][Full Text] [Related]
38. Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1β and rapid response to anakinra.
Sabroe RA; Stokes CA; Parker LC; Higgins K; Prince LR; Sabroe I
Clin Exp Dermatol; 2013 Dec; 38(8):874-7. PubMed ID: 23889084
[TBL] [Abstract][Full Text] [Related]
39. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: successful use of vemurafenib.
Schirmer JH; Thorns C; Moosig F; Holle JU
Rheumatology (Oxford); 2015 Oct; 54(10):1932-4. PubMed ID: 26139656
[No Abstract] [Full Text] [Related]
40. Cryopyrin-associated periodic syndrome.
Posch C; Kaulfersch W; Rappersberger K
Pediatr Dermatol; 2014; 31(2):228-31. PubMed ID: 22891689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
